Gefitinib: Quiz

Question 1: Gefitinib is an ________, like erlotinib, selectively targeting proteins in malignant cells.
Src (gene)ErbBCD117Epidermal growth factor receptor

Question 2: Gefitinib inhibits EGFR tyrosine kinase by binding to the ________ (ATP)-binding site of the enzyme.
Adenosine diphosphateAdenosine monophosphateAdenosine triphosphateCytidine triphosphate

Question 3: Of the types of non-small cell lung cancer histologies, ________ is the type that most often harbors these mutations.
Krukenberg tumorICD-10 Chapter II: NeoplasmsSquamous cell carcinomaAdenocarcinoma

Question 4: ________ is another EGFR tyrosine kinase inhibitor that works in the same way as gefitinib.

Question 5: Gefitinib is currently only indicated for the treatment of locally advanced or metastatic ________ (NSCLC) in patients who have previously received chemotherapy.
Non-small cell lung carcinomaSolitary pulmonary noduleSmall cell carcinomaMesothelioma

Question 6: Gefitinib is the first selective inhibitor of ________'s (EGFR) tyrosine kinase domain.
ErbBCD117Epidermal growth factor receptorSrc (gene)

Question 7: lymphoid: ________ (Ibritumomab, Ofatumumab, Rituximab, Tositumomab), CD52 (Alemtuzumab)

Question 8: Research on gefitinib-sensitive ________ has shown that a mutation in the EGFR tyrosine kinase domain is responsible for activating anti-apoptotic pathways.
Small cell carcinomaNon-small cell lung carcinomaMesotheliomaSolitary pulmonary nodule

Question 9: Gefitinib (INN) (pronounced /ɡɛˈfɪtɨnɪb/) (Iressa) is a drug used in the treatment of certain types of ________.

Source: The Full Wiki (